We are passionate to deliver first in class cancer drugs to patients.
To be an R&D oriented pharmaceutical company based in Japan.
We are passionate to deliver first in class cancer drugs to patients from Japan.
Chordia Therapeutics is a biotech company engaged in research and development of novel therapies for cancers.
Professionals who have deep knowledge and experience for oncology area keep on striving toward developing new drugs that will envision the tomorrow of cancer treatment.
In general, it takes a long time for bringing out a new drug to patients.
And we also need the cooperation from collaborators and supporters.
So, the thing that our company always cares about is the speedy research and development which is derived from quick decision-making as an R&D oriented biotech, and the gratitude to our external partners who support our company.
We are advancing drug development quickly and steadily by making the best use of the flexibility of lean organization, broad network of experienced professionals, and the accumulated R&D wisdom.
Out lead asset CLK inhibitor CTX-712, currently under first-stage of clinical trials, has a novel mode of action that kills cancer cells by altering mRNA splicing.
The key to the sustainable growth of biotech companies is the successful development of new drugs, and we aspire to deliver the first in class anti-cancer drug from Japan to patients around the world as soon as possible by leveraging our strengths.
Board of Directors
Kyoto Innovation Capital
Shinsei Venture Capital
Lead and accelerate a life science eco-system and various players (e.g. Academia, Pharma Company, Investor, Government, CRO (Contract Research Organization and so on) to realize drug discovery process.
Chordia is focusing on Research and Development of anti-cancer drug from target discovery to Proof of Concept (POC). Chordia is also flexible organization structure for maximizing value of patient and company by corresponding to strategic partner’s proposals.
Chordia is derived from the word ‘chord’, which are musical notes that sound pleasant when played together.
Like a chord, we are working towards harmonizing our energy and passion for science with our collaborators, supporters, and stakeholders to enable the discovery of innovative drugs.
Our corporate colors are Navy Peony as a main color, and Greenery as a sub color selected from PANTONE Color. Navy Peony is a dependable and an anchoring shade, and Greenery is a refreshing and revitalizing one.
Greenery is Pantone Colour of the Year 2017, which is also Chordia’s start-up year.
Logomark is designed by Nonoka Imai
Our corporate symbol is derived from leaf and fruit of China root (Smilax china), and symbolizes our never-give-up attitude which is its floriography.
Furthermore, two leaves and three berries delineate our cudding figure with patient, and drugs to be delivered to patients, respectively.
- Corporate Name
- Chordia Therapeutics Inc.
- November 1, 2017
- Head Office
- 26-1, Muraoka-Higashi 2-chome, Fujisawa,Kanagawa, 251-0012 Japan
- Tokyo Office
- 3-11-5, Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023 Japan
- Hiroshi Miyake, Ph.D. CEO
- October 2017
- Launch of Chordia Therapeutics
- November 2017
- Raises $~11 million in Series A Financing
- November 2018
- Initiate Phase 1 Study for CTX-712
- March 2019
- Raises $~27 million in Series B Financing
- December 2020
- Notice of license agreement with Ono Pharmaceutical
- May 2022
- Raises $~31 million in Series C Financing